Results 331 to 340 of about 5,260,709 (398)

Recent advances in PLGA polymer nanocarriers for ovarian cancer therapy. [PDF]

Front Oncol
You T, Zhang S.
europepmc   +1 more source

Cell Membrane‐Coated Lipid Nanoparticles for Drug Delivery

Aggregate, EarlyView.
This review highlights recent progress in cell membrane‐coated lipid nanoparticles (CMC‐LNPs), focusing on their design, preparation methods, functional integration, and biomedical applications. It discusses various types of LNPs and coating strategies, characterization techniques, therapeutic functions, and applications.
Moataz B. Zewail, Guangze Yang, Yilong Fan, Yue Hui, Chun‐Xia Zhao, Yun Liu   +5 more
wiley   +1 more source

The intersection of ferroptosis and non-coding RNAs: a novel approach to ovarian cancer. [PDF]

Eur J Med Res
Jiang Y, Saeed TN, Alfarttoosi KH, Bishoyi AK, Rekha MM, Kundlas M, Jain B, Rizaev J, Taher WM, Alwan M, Jawad MJ, Ali Al-Nuaimi AM.   +11 more
europepmc   +1 more source

Polymerase chain reaction allelotyping of human ovarian cancer

, 1994
RJ Osborne, Vanessa Leech
openalex   +1 more source

Multi‐Module Micro/Nanorobots for Biomedical and Environmental Remediation Applications

Advanced Intelligent Systems, EarlyView.
Multi‐module microrobots (MNRs) have overcome the limitations of single‐module systems by integrating components such as propeller, actuator, manipulator, and imaging modalities. They show promise in biomedical applications, such as targeted drug delivery and tissue repair, as well as in environmental remediation, including pollutant removal.
Bairong Zhu, Amar Salehi, Lei Xu, Wei Yuan, Tingting Yu   +4 more
wiley   +1 more source

Intraperitoneal chemotherapy is now back for ovarian cancer. [PDF]

Int J Clin Oncol
Fujiwara K, Nagao S, Tan D, Hasegawa K.
europepmc   +1 more source

Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model

, 1994
Barbara A. Goff, Ulrich Hermanto, Jeffrey A. Rumbaugh, J Blake, M. Bamberg, Tayyaba Hasan   +5 more
openalex   +1 more source

TP53‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, EarlyView.
ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations (TP53mut) and present immense challenges due to inherent chemoresistance and poor outcomes.
Mithun Vinod Shah, Daniel A. Arber, Devendra K. Hiwase   +2 more
wiley   +1 more source

Topics of Interest in Women With Myeloproliferative Neoplasms

American Journal of Hematology, EarlyView.
Women with MPN: life‐cycle phases, specific risks, and influencing factors. ABSTRACT Overview Sex and gender have emerged as central modifiers of disease biology, phenotype, and clinical outcomes in myeloproliferative neoplasms (MPNs). This review will uniquely highlight issues affecting women with MPN and articulate their relevant determinants ...
Natasha Szuber, Paola Guglielmelli, Naseema Gangat   +2 more
wiley   +1 more source

AKT1 as a therapeutic target for platinum-resistant SOX2 positive ovarian cancer cells. [PDF]

Sci Rep
Xue M, Kang L, Zhang Y, Yuan X, Li J, Zhang R, Wong J.   +6 more
europepmc   +1 more source